State of New Jersey Common Pension Fund D Invests $1.59 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN)

State of New Jersey Common Pension Fund D bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 44,197 shares of the company's stock, valued at approximately $1,588,000.

Several other hedge funds also recently modified their holdings of DYN. Nisa Investment Advisors LLC boosted its holdings in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock valued at $26,000 after acquiring an additional 669 shares during the period. US Bancorp DE lifted its position in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock worth $49,000 after purchasing an additional 1,212 shares during the last quarter. Values First Advisors Inc. bought a new stake in Dyne Therapeutics during the 3rd quarter valued at approximately $62,000. Amalgamated Bank grew its holdings in Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company's stock valued at $99,000 after buying an additional 796 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Dyne Therapeutics by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company's stock worth $123,000 after buying an additional 709 shares during the period. Institutional investors and hedge funds own 96.68% of the company's stock.

Insider Activity

In other Dyne Therapeutics news, CEO John Cox purchased 32,000 shares of the stock in a transaction dated Wednesday, September 4th. The stock was bought at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the transaction, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. This represents a -133.33 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the company's stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares of the company's stock, valued at $4,529,594.76. The trade was a 6.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 176,257 shares of company stock valued at $6,193,718 over the last three months. 20.77% of the stock is owned by insiders.

Dyne Therapeutics Trading Down 0.6 %

DYN traded down $0.18 during trading on Tuesday, hitting $29.16. The company's stock had a trading volume of 291,777 shares, compared to its average volume of 1,488,565. The firm's 50 day moving average price is $32.42 and its two-hundred day moving average price is $35.26. Dyne Therapeutics, Inc. has a 12 month low of $10.03 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). Analysts predict that Dyne Therapeutics, Inc. will post -3.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DYN has been the topic of several research analyst reports. Oppenheimer restated an "outperform" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Chardan Capital reiterated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Stifel Nicolaus increased their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. Finally, Guggenheim lifted their price objective on Dyne Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.